miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.


miRdetect Receives Seed Financing – Consortium Invests Seven-Digit Amount in Serum Marker for Testicular Cancer Detection

High-Tech Gründerfonds (HTGF), BAB Beteiligungs- und Managementgesellschaft Bremen mbH (BBM) and a private investor invest in Bremen start-up miRdetect miRdetect develops an innovative and accurate test method for the detection of testicular cancer Together with BBM and a private investor, High-Tech Gründerfonds…


Fahrenheitstraße 1
28359 Bremen

In portfolio

14. Dec 2018